The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly ...

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

The digital revolution has brought more efficient ways to reach and touch HCPs.

Industry veteran Charles Pirraglia demystifies the journey of bringing life-changing therapies to the Canadian market, from understanding drug pricing to navigating direct-to-consumer advertising ...

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.

Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell ...

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...